Natera is a global diagnostic company specializing in cell-free DNA (cfDNA) testing and genetic diagnostics across oncology, women's health, and organ health. The company operates CLIA-certified, CAP-accredited laboratories in Austin, Texas and San Carlos, California, with ISO 13485 certification, and serves patients and healthcare providers worldwide.
The company's diagnostic portfolio includes Panorama, a prenatal screening test; Signatera, a personalized cancer detection test; and Prospera, a transplant monitoring test. Natera's proprietary technology platform achieves analytical sensitivity enabling detection down to a single molecule in a tube of blood, supported by a research foundation of more than 300 peer-reviewed publications.
Natera's approach emphasizes earlier and more targeted health interventions through personalized genetic testing integrated into standard clinical care. The company combines expertise in molecular biology, bioinformatics, and artificial intelligence to develop tests that inform clinical decision-making across its therapeutic areas.